by Redaktion LCGC | Oct 18, 2015
Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors. Heigener DF, Schumann C, Sebastian M, Sadjadian P, Stehle I, Märten A, Lüers A, Griesinger F, Scheffler M Journal: Oncologist Veröffentlichung: 20....
by Redaktion LCGC | Oct 10, 2015
Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort. Meder L, König K, Ozretić L, Schultheis AM, Ueckeroth F, Ade CP, Albus K, Boehm D, Rommerscheidt-Fuss U, Florin A, T Buhl, Hartmann W, Wolf J, Merkelbach-Bruse S, M...
by Redaktion LCGC | Sep 4, 2015
NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas. Meder L, König K, Ozretić L, Schultheis AM, Ueckeroth F, Ade CP, Albus K, Boehm D, Rommerscheidt-Fuss U, Florin A, T Buhl, Hartmann W, Wolf J,...
by Redaktion LCGC | Aug 19, 2015
A Modeling and Simulation Framework for Adverse Events in Erlotinib-Treated Non-Small-Cell Lung Cancer Patients. Suleiman AA, Frechen S, Scheffler M, Zander T, Nogova L, Kocher M, Jaehde U, Wolf J, Fuhr U. Journal: AAPS J. published: August 19th,...
by Redaktion LCGC | Aug 18, 2015
Impact of PET/CT image reconstruction methods and liver uptake normalization strategies on quantitative image analysis. Kuhnert G, Boellaard R, Sterzer S, Kahraman D, Scheffler M, Wolf J, Dietlein M, Drzezga A, Kobe C. Journal: Eur J Nucl Med Mol Imaging...
